MET and non-small cell lung carcinoma: Even in patients with high PD-L1 expression, immunotherapy has shown limited efficacy in MET-driven NSCLC, and there is growing evidence that MET exon 14 mutations may confer resistance to immune checkpoint blockade [9,10].